The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells

References

• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57–70.
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804–815.
   PubMed Web of Science ®Google Scholar
• Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324–1337.
   PubMed Web of Science ®Google Scholar
• Sattler M, Liang H, Nettesheim D, et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997;275:983–986.
   PubMed Web of Science ®Google Scholar
• Liu X, Dai S, Zhu Y, et al. The structure of a Bcl-xL/Bim fragment complex: implications for Bim function. Immunity 2003;19: 341–352.
   PubMed Web of Science ®Google Scholar
• Kuwana T, Bouchier-Hayes L, Chipuk JE, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005;17:525–535.
   PubMed Web of Science ®Google Scholar
• Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17:393–403.
   PubMed Web of Science ®Google Scholar
• Willis SN, Fletcher JI, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007;315:856–859.
   PubMed Web of Science ®Google Scholar
• Kitada S, Pedersen IM, Schimmer AD, et al. Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 2002;21: 3459–3474.
   PubMed Web of Science ®Google Scholar
• Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 2007;109:271–280.
   PubMed Web of Science ®Google Scholar
• Al-Harbi S, Hill BT, Mazumder S, et al. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood 2011;118:3579–3590.
   PubMed Web of Science ®Google Scholar
• Dong HJ, Zhou LT, Zhu DX, et al. The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13). Ann Hematol 2011;90:709–717.
   PubMedGoogle Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307–310.
   PubMed Web of Science ®Google Scholar
• Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001;7:683–694.
   PubMed Web of Science ®Google Scholar
• Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000;288:1053–1058.
   PubMed Web of Science ®Google Scholar
• Mérino D, Strasser A, Bouillet P. Bim must be able to engage all pro-survival Bcl-2 family members for efficient tumor suppression. Oncogene 2012;31:3392–3396.
   PubMed Web of Science ®Google Scholar
• Happo L, Cragg MS, Phipson B, et al. Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. Blood 2010;116:5256–5267.
   PubMed Web of Science ®Google Scholar
• Mackus WJ, Kater AP, Grummels A, et al. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia 2005;19:427–434.
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Xu W, Cao X, et al. Detection of puma mRNA levels by real-time quantitative RT-PCR in chronic lymphocytic leukemia and its clinical significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010;18: 843–848.
   PubMedGoogle Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198–206.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhang Y, Zheng W, et al. Distinctive IgVH gene segments usage and mutation status in Chinese patients with chronic lymphocytic leukemia. Leuk Res 2008;32:1491–1498.
   PubMed Web of Science ®Google Scholar
• Xu W, Li JY, Wu YJ, et al. CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia. Leuk Res 2009;33:237–243.
   PubMed Web of Science ®Google Scholar
• Xu W, Li JY, Wu YJ, et al. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia. Leuk Res 2008;32:1071–1077.
   PubMed Web of Science ®Google Scholar
• Zenz T, Häbe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009;114:2589–2597.
   PubMed Web of Science ®Google Scholar
• Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998;91:3379–3389.
   PubMed Web of Science ®Google Scholar
• López-Royuela N, Pérez-Galán P, Galán-Malo P, et al. Different contribution of BH3-only proteins and caspases to doxorubicin-induced apoptosis in p53-deficient leukemia cells. Biochem Pharmacol 2010;79:1746–1758.
   PubMed Web of Science ®Google Scholar
• Iglesias-Serret D, de Frias M, Santidrián AF, et al. Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells. Leukemia 2007;21:281–287.
   PubMed Web of Science ®Google Scholar
• Cragg MS, Harris C, Strasser A, Scott CL. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer 2009;9:321–326.
   PubMed Web of Science ®Google Scholar
• Yu J, Wang Z, Kinzler KW, et al. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 2003;100:1931–1936.
   PubMed Web of Science ®Google Scholar
• Michalak EM, Villunger A, Adams JM, et al. In several cell types the tumour suppressor, p53, induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ 2008;15:1019–1029.
   PubMed Web of Science ®Google Scholar
• Kaeser MD, Iggo RD. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci USA 2002;99: 95–100.
   PubMed Web of Science ®Google Scholar
• Armstrong JL, Veal GJ, Redfern CP, et al. Role of Noxa in p53-independent fenretinide-induced apoptosis of neuroectodermal tumours. Apoptosis 2007;12:613–622.
   PubMed Web of Science ®Google Scholar
• Wu WS, Heinrichs S, Xu D, et al. Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 2005;123:641–653.
   PubMedGoogle Scholar
• Jeffers JR, Parganas E, Lee Y, et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003;4:321–328.
   PubMed Web of Science ®Google Scholar
• Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003;302:1036–1038.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10:375–388.
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Gonen M, Bhagat G, et al. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 2008;112:2906–2916.
   PubMed Web of Science ®Google Scholar